Novel trypsin isoforms and uses thereof
By developing a novel trypsin ZT allotype, the problem of insufficient trypsin purification in the prior art is solved, and an effective antimicrobial agent for viruses and bacteria is provided for the treatment and prevention of upper respiratory tract diseases and wound infections is provided. , realizes efficient application in the medical and cosmetics fields.
Patent Information
- Application Number
- CN202111184339.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-07-24
- Filing Date
- 2016-07-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2036-07-22
AI Technical Summary
The prior art lacks pure trypsin or trypsin mixtures for pharmaceutically applicable products, and the purification and characterization of trypsin is insufficient, making it difficult to meet the efficient application needs of medical and cosmetics.
A novel trypsin isoform, called trypsin ZT isoform, was developed to form a composition for use in the composition of the Treat and prevent diseases caused by pathogenic organisms, especially for upper respiratory tract diseases and wound infections.
Trypsin ZT isoforms show preference for cleavage at Arg residues, have significant antimicrobial properties, and are able to effectively cleave peptides containing continuous basic amino acid residues, as antimicrobial agents against viruses and bacteria, improving Effects of treating and preventing diseases.
Smart Images

Figure CN113846079B_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201680042929.8 and invention name “Novel trypsin isoforms and their uses”. The parent application is the PCT international patent application PCT / EP2016 / 067531 filed on July 22, 2016, which entered the Chinese national phase. Technical Field
[0002] The present invention relates to novel trypsin ZT isoforms, and more particularly to the use of trypsin ZT isoforms in medical devices, medicines and cosmetics. Background Art
[0003] Proteases are enzymes defined by their ability to cleave proteins. Proteases can cleave substrates at different amino residues within a protein sequence, showing differences in substrate specificity. Trypsin is a protease and is specified in part by its preference for cleaving the C-terminus to either arginine or lysine residues (Olsen, Ong et al., 2004, Mol Cell Proteomics 3:608-614). Multiplex substrate analysis methods reveal the cleavage site of a protease and disclose the critical importance of the residues surrounding its cleavage site for its specificity (O'Donoghue, Eroy-Reveles et al., 2012, Nat Methods 9:1095-1100).
[0004] U.S. Patent Nos. 4,801,451 and 4,963,491 disclose mixtures of exopeptidases and endopeptidases isolated from Antarctic krill (Euphasia superba) and the use of such mixtures as cleaning solutions. 4,801,451 discloses the use of such enzymes to remove foreign matter and necrotic tissue from wounds. WO 85 / 04809 discloses the use of krill enzymes as digestion enhancers. EP-A1-0170115 discloses the use of krill enzymes to dissolve blood clots. However, all of these references disclose impure or inadequately characterized materials. Pure peptidases or mixtures of pure peptidases are needed to provide pharmaceutically useful products.
[0005] WO 96 / 24371 discloses a krill-derived multifunctional proteolytic enzyme and the use of a family of proteolytic enzymes derived from crustaceans and fish that have structural similarity to the multifunctional enzyme derived from Antarctic krill. The document also relates to methods for purifying the multifunctional enzyme and pharmaceutical, cosmetic and other uses of the multifunctional enzyme. Structural similarity to the multifunctional enzyme derived from Antarctic krill is defined in the document as having at least 70% homology to the krill-derived multifunctional hydrolase.
[0006] WO 2000078332 discloses the use of cod-derived trypsin and chymotrypsin in pharmaceutical compositions or medicaments for topical and topical application to treat internal diseases and conditions, and cosmetic uses of such enzymes. It was found that topical use for treating local, internal conditions is effective without the enzyme having to pass through open wounds or mucous tissue. The serine proteases disclosed in WO 2000078332 are proteases having at least 90% amino acid sequence homology with trypsin I, trypsin II, trypsin III, trypsin IV derived from Atlantic cod, and proteases satisfying the following condition: chymotrypsin having at least 90% amino acid sequence homology with any of chymotrypsin A and chymotrypsin B isolated from Atlantic cod.
[0007] The complementary DNA (cDNA) encoding trypsin Y was isolated from an Atlantic cod cDNA library (Spilliaert and Gudmundsdottir, 1999, Mar Biotechnol (NY) 1: 598-607). Cod trypsin Y has approximately 45% identity to the two Atlantic cod trypsins I and X (WO 2000078332). Native trypsin Y and recombinant forms of trypsin Y have been briefly described previously (Palsdottir and Gudmundsdottir, 2007, Protein Expr Purif 51: 243-252, Palsdottir and Gudmundsdottir, 2008, Food Chemistry 111: 408-414). Summary of the invention
[0008] The present invention provides novel trypsin isoforms, termed trypsin ZT isoforms. Such isoforms can be obtained from fish, such as Atlantic cod, or can be obtained in recombinant form using a protein expression system. The present invention further provides a composition comprising at least one isolated cod trypsin ZT isoform according to the present invention and suitable excipients and carriers.
[0009] The inventors have surprisingly discovered that novel trypsin ZT isoforms have advantageous and unique features compared to previously known trypsins. These features provide advantages for using trypsin ZT isoforms in various applications of medical devices, pharmaceuticals and cosmetics. The present invention provides the trypsin ZT isoforms themselves and for use in treating or preventing diseases caused by pathogenic organisms. This is particularly relevant for use in treating or preventing upper respiratory tract diseases caused by pathogenic microorganisms. For the purposes described, the trypsin ZT isoforms can be used, for example, in medical devices, or as an active ingredient in a medicament. In addition, the present invention provides the trypsin ZT isoforms for use in treating wound infections and wounds caused by burns, for removing necrotic or exfoliated skin from otherwise healthy skin (e.g. in medical devices), for use as a medicament or as a cosmetic. The present invention further provides methods for preparing the cod trypsin ZT isoforms of the present invention.
[0010] Based on the multivariate substrate profile, trypsin ZT isoforms prefer to cleave at Arg residues compared to trypsin I. Trypsin I prefers to cleave at Lys residues compared to trypsin ZT isoforms.
[0011] The multivariate substrate distribution showed that different amino acid residues in the substrate around the cleavage site had a greater impact on cleavage (about four amino acid residues on the N-terminal side and about four amino acid residues on the C-terminal side). Compared with trypsin I, trypsin ZT isoforms prefer certain amino acid residues around the cleavage site.
[0012] Arginine- and lysine-rich amino acid sequences are often found in viral, bacterial, and parasitic sequences associated with infection.
[0013] The values based on the standard score (Z-score) ratios (multivariate substrate distribution data) show that the trypsin ZT isoform is significantly better suited to cleaving peptides containing several consecutive basic amino acid residues (Arg and Lys) compared to trypsin I. Based on the data, the trypsin ZT isoform may act as an antimicrobial agent against viruses and bacteria because it can cleave at clustered basic amino acid residues such as lysine and arginine. DETAILED DESCRIPTION OF THE INVENTION
[0015] The present invention provides novel trypsin isoforms, termed trypsin ZT isoforms. Such isoforms can be obtained from fish, such as Atlantic cod, or can be obtained in recombinant form using a protein expression system. The present invention relates to the use of such trypsin ZT isoforms for the treatment and prevention of disease and in the cosmetic field. In particular, the present invention relates to novel Atlantic cod trypsin ZT isoforms, which are suitable for use as pharmaceuticals, medical devices and cosmetics. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 The separation of trypsin ZT isoforms performed with anion exchange chromatography is shown. The chromatogram from the MonoQ separation of codfish trypsin isoforms purified with benzamidine is shown at absorbance at 280nm relative to elution volume. Codfish trypsin isoforms are loaded onto the MonoQ column and eluted with salt gradient (dotted line) protein. The arrow shows the peak containing trypsin ZT isoforms. The column is balanced with buffer (20mM Tris, 10mM CaCl2, pH 8.0), and the enzyme is eluted with a linear 0-150mM NaCl gradient for 40 times of column volumes, a linear 150-620mM NaCl for 6 times of column volumes, and a 620-850mM NaCl elution for 10 times of column volumes at a flow rate of 1mL / min.
[0017] Figure 2 SDS-PAGE showing cod trypsin ZT isoforms. Figure 1 Figure 10 shows an anion exchange chromatography peak labeled with trypsin ZT from SDS-PAGE. Trypsin 1, trypsin 5 and trypsin 7 are purified and isolated cod trypsin X isoforms. Cod trypsin X is closely related to cod trypsin I, differing by about eight amino acid residues. The proteins were resolved by SDS-PAGE and stained with gel silver. The bars and numbers on the left show the migration and molecular weight (kDa) of the standard protein (Dalton Mark Vll-L) separated on the gel.
[0018] Figure 3 Western blot analysis showing codfish trypsin X (trypsin 1, trypsin 5 and trypsin 7) and trypsin ZT isoforms. Codfish trypsin X and trypsin ZT isoforms were subjected to SDS-PAGE. After transfer, samples were immunoblotted with antibodies reactive with trypsin 1 / X (upper panel) and trypsin ZT isoforms (lower panel). This demonstrates the separation of trypsin ZT isoforms from trypsin 1 / X using anion exchange. Figure 3 As can be seen, the polyclonal antibody reactive against the trypsin ZT isoform does not cross-react with trypsin 1 / X and the antibody against the peptide with elevated trypsin 1 / X does not cross-react with the trypsin ZT isoform.
[0019] Figure 4Shown is a Venn diagram illustrating the common and unique cleavages by Trypsin ZT and Trypsin I at three different time points in a multivariate substrate distribution analysis. The number of common (black) and unique cleavage sites by Trypsin ZT (white on the left) and Trypsin I (white on the right) after 5 minutes of incubation. (A), 15 minutes. (B) and 60 minutes (C). The graph shows the presence of common and unique cleavage sites for Trypsin ZT and Trypsin I in 124 defined peptides (each containing 14 amino acid residues) within the library at all time points. The data indicate that the substrate specificity of Trypsin ZT is different from that of Trypsin I.
[0020] Figure 5 Shows antiviral activity of trypsin ZT against enterovirus (Coxsackievirus B2).
[0021] The Y-axis shows the percentage of infected wells compared to control, and the X-axis shows control (left bar) and treatment with the Trypsin ZT isoform (right bar). DETAILED DESCRIPTION
[0022] The present inventors have discovered novel trypsin isoforms, termed trypsin ZT isoforms.
[0023] Trypsin ZT includes at least the following isoforms: Atlantic cod trypsin ZT-1 isoform, Atlantic cod trypsin ZT-2 isoform, Atlantic cod trypsin ZT-3 isoform, and Atlantic cod trypsin ZT-4 isoform. All four Atlantic cod trypsin ZT isoforms have a similar molecular weight of about 25 kDa. The Atlantic cod trypsin ZT isoform of the present invention is represented by the following amino acid sequence:
[0024] SEQ ID NO: 1
[0025]
[0026] in
[0027] X1 is selected from I and V;
[0028] X2 is selected from Q and H;
[0029] X3 is selected from D and E;
[0030] X4 is selected from R and N;
[0031] X5 is L;
[0032] X6 is selected from T and P;
[0033] X7 is selected from D and A;
[0034] X8 is selected from E and Q;
[0035] X9 is selected from A and S;
[0036] X 10 Selected from V and M;
[0037] X 11 Selected from A and V;
[0038] X 12 Selected from Y and F;
[0039] X 13 Selected from A and V;
[0040] X 14 Selected from Q and R;
[0041] X 15 Selected from L and E;
[0042] X 16 is selected from Y and S; and
[0043] X 17 Selected from Y and F.
[0044] SEQ ID NO: 2 Atlantic cod trypsin ZT-1 isoform
[0045]
[0046] SEQ ID NO: 3 Atlantic cod trypsin ZT-2 isoform
[0047]
[0048] SEQ ID NO: 4 Atlantic cod trypsin ZT-3 isoform
[0049]
[0050] SEQ ID NO: 5 Atlantic cod trypsin ZT-4 isoform
[0051]
[0052] The trypsin ZT isoform of the present invention has less than 50% amino acid homology with the trypsin disclosed in WO 2000078332 and less than 45% homology with the chymotrypsin disclosed in WO 2000078332.
[0053] The above trypsin ZT isoforms represent active variants of these trypsins, i.e., variants that are already activated when the N-terminus of the trypsin is cleaved. These trypsins are proteins expressed in Pylori (pancreatic tissue in fish), in which many amino acids at the N-terminus are important for cellular secretion and maintaining enzyme inactivation. Full-length trypsin ZT isoforms are also disclosed herein, such as
[0054] SEQ ID NO: 19 Uncleaved Atlantic cod trypsin ZT-1 isoform
[0055]
[0056] SEQ ID NO: 20 Uncleaved Atlantic cod trypsin ZT-2 isoform
[0057]
[0058] SEQ ID NO: 21 Uncleaved Atlantic cod trypsin ZT-3 isoform
[0059]
[0060] SEQ ID NO: 22 Uncleaved Atlantic cod trypsin ZT-4 isoform
[0061]
[0062] The substrate specificity of enzymes (proteases) is analyzed using multivariate substrate profiling (O'Donoghue, Eroy-Reveles et al., 2012, Nat Methods 9: 1095-1100). Proteases can cleave substrates at different amino residues within a peptide sequence, indicating differences in substrate specificity. Trypsin is specified by its preference for cleaving the C-terminus to either arginine or lysine residues. Unexpectedly, multivariate substrate profiling on trypsin ZT isoforms indicated that amino acids surrounding arginine or lysine in the substrate had different effects on its cleavage compared to trypsin I. Briefly, trypsin ZT isoforms or trypsin I were incubated (5, 15, and 60 minutes) with a peptide library with broad physiochemical diversity (124 defined peptides, 14-mer sequences, 1612 peptide bonds in total) (O'Donoghue, Eroy-Reveles et al., 2012, Nat Methods 9: 1095-1100). After incubation, the cleavage sites were identified by mass spectrometry. The results are presented in the following examples and confirm that there are a large number of cleavage sites unique to trypsin ZT compared to trypsin I. Moreover, the identification shows that the cleavage sites that are preferentially cleaved by trypsin ZT isoforms compared to trypsin I. In addition, compared to trypsin I disclosed in WO 2000078332, the novel trypsin ZT isoforms have different substrate specificities. These findings are unexpected. Based on the results from the multivariate substrate distribution analysis, a table containing numerical values based on the ratio of standard scores (Z scores) at the P4-P4′ position in the substrate is generated, wherein the substrate specificity of trypsin ZT and trypsin I is compared. Positive values (Z scores) reflect that the preference of amino acid residues in a certain P position favors trypsin ZT isoforms compared to trypsin I.
[0063] Trypsin ZT isoforms have specific antimicrobial properties. Based on the values generated and presented in the examples, it can be found that trypsin ZT isoforms are significantly more suitable for cleaving peptides containing several consecutive positively charged residues (arginine or lysine) compared to trypsin I. These types of sequences (amino acid sequences rich in lysine and arginine) are often found in viral proteins (Suzuki, Orba et al., 2010, PLoS Pathog 6:e1000801, Jiang, Cun et al., 2012, J Virol 86:7256-7267, Gallaher and Garry, 2015, Viruses 7:285-305).
[0064] Viroporins are a group of proteins that interact with the plasma membrane to modify permeability and promote the release of viral particles. Aggregated lysine and / or arginine residues are important for the activity of viroporins. Based on multivariate substrate distribution analysis, trypsin ZT isoforms can act as antiviral agents against RNA viruses because they can cleave these aggregated basic amino acid residues. Viroporins have been described in many virus families, including Flaviviridae, Picornaviridae, Retroviridae, Coronaviridae, Reoviridae, and Paramyxoviridae (Royle, Dobson et al., 2015, Viruses 7: 5375-5387). Studies have shown that basic residues in viroporins, lysine or arginine, are important requirements for their function. Most viroporins have been found in RNA viruses. Viruses containing lysine- and arginine-rich viroporins will be targeted by trypsin ZT isoforms, including human immunodeficiency virus (HIV), rotavirus, Ebola virus (Ebola), Reston virus (RESTV), Lloviu virus (LLOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus (TAFV) (Suzuki, Orba et al., 2010, PLoS Pathogens 6:e1000801, Gallaher and Garry, 2015, Viruses 7:285-305).
[0065] Viroporins are found in a wide variety of DNA and RNA viruses, such as Parameciumbursaria chlorella virus 1, simian virus 40 (SV40), human polyomavirus JC (JCV), severe acute respiratory syndrome coronavirus (SARS-CoV) (Kang, Moroni et al., 2004, Proc Natl Acad Sci USA 101:5318-5324, Liao, Tam et al., 2006, Adv Exp Med Biol 581:199-202, Daniels, Sadowicz et al., 2007, PLoS Pathogens 3:e98).
[0066] Strongly basic viral proteins, called unidentified proteins, have recently been discovered from DNA viruses, such as from Polyomaviridae and Papillomaviridae (Royle, Dobson et al., 2015, Viruses 7:5375-5387). These proteins display many characteristics of viroporins. Conserved sequences containing many aggregated basic amino acid residues have been found in unidentified proteins (Royle, Dobson et al., 2015, Viruses 7:5375-5387). Based on multivariate substrate distribution analysis, trypsin ZT isoforms may act as antiviral agents against DNA viruses because they can cleave these aggregated basic amino acid residues (Royle, Dobson et al., 2015, Viruses 7:5375-5387).
[0067] Many viruses and bacteria have developed mechanisms to achieve cellular entry using cell-penetrating peptides or proteins (Milletti, 2012, Drug Discov Today 17: 850-860). Viruses include pestiviruses of the Flaviviridae family, herpesvirus (HSV-1), human immunodeficiency virus (HIV-1, hepatitis B, and human respiratory syncytial virus (RSV) (Elliott and O'Hare, 1997, Cell 88:223-233, Oess and Hildt, 2000, Gene Ther 7:750-758, Langedijk, 2002, J Biol Chem 277:5308-5314, Langedijk, Olijhoek et al., 2005, International Congress Series 1277:95-107, Lu, Taeer et al., 2006, Anal Biochem 353:7-14, Godet, Guergnon et al., 2010, PLoS One》5:e13760). In addition, these types of proteins have been found in bacteria, such as Mycobacterium tuberculosis (Lu, Tager et al., 2006, Analytical Biochemistry 353:7-14). A common feature of cell-penetrating peptides (CPPs) is that they are rich in basic amino acid residues, especially arginine (Milletti, 2012, Drug Discovery Today 17:850-860). Porins are outer membrane proteins that play a key role in bacterial pathogenicity and protection and, for this reason, are suitable targets for therapeutic agents (Galdiero, Falanga et al., 2012, Curr Protein Pept Sci 13:843-854). These proteins often contain consecutive arginine amino acid residues. Based on multivariate substrate distribution analysis, trypsin ZT isoforms can act as antibacterial agents against viruses and bacteria because they can cleave aggregated basic amino acid residues.
[0068] Parasites depend on virulence determinants such as proteins containing arginine-rich domains, such as Toxoplasma gondii (Fentress, Steinfeldt et al., 2012, Cell Microbiol 14: 1921-1933). Multivariate substrate distribution analysis suggests that trypsin ZT isoforms may be beneficial against parasites by acting on such proteins.
[0069] The Basic Local Alignment Search Tool (BLAST) was used to search for some unique and preferred amino acid sequences cleaved by trypsin ZT isoforms. The search results showed that these types of sequences were found in many pathogens, including viruses (e.g., from the Paramyxoviridae and Coronaviridae families of viruses), bacteria (e.g., Haemophilus genus), and parasites (e.g., Plasmodium genus). The Paramyxoviridae family includes viruses such as respiratory syncytial virus (RSV) and human parainfluenza virus, as well as viruses that cause mumps and measles. The Coronaviridae family includes viruses that cause severe acute respiratory syndrome (SARS). The bacterial Haemophilus genus includes Haemophilus parainfluenzae, which is associated with endocarditis, meningitis, and bacteremia. The Plasmodium genus includes Plasmodium falciparum, which causes malaria.
[0070] The phrase "medical device" means, but is not limited to, any instrument, apparatus, appliance, software, material or other article used for the purpose of diagnosis, prevention, monitoring, treatment or alleviation of disease, such as diagnosis, monitoring, treatment, alleviation or compensation; for the study, replacement or modification of injuries or disorders, such as anatomical structures or physiological processes; concept control; including devices that do not achieve their primary desired effect in or on the human body by pharmacological, immunological or metabolic means, but whose function can be assisted by such means.
[0071] The present invention relates to novel trypsin ZT isoforms. The present invention describes trypsin ZT isoforms with unexpected and unique protein cleavage properties, making them valuable in medical applications. Specifically, the present invention relates to novel Atlantic cod trypsin ZT isoforms, which are suitable for use as pharmaceuticals, medical devices and cosmetics.
[0072] In one aspect of the present invention, an isolated cod trypsin ZT isoform is provided, comprising an amino acid sequence according to SEQ ID NO: 1, or an amino acid sequence having 80% or more sequence homology thereto. Typically, such sequence homology is 85, 90, 95 or 99% homologous to the amino acid sequence of SEQ ID NO: 1.
[0073] In one embodiment of this aspect, an isolated cod trypsin ZT isoform is provided, selected from trypsin ZT-1, comprising the amino acid sequence according to SEQ ID NO: 2; trypsin ZT-2, comprising the amino acid sequence according to SEQ ID NO: 3; trypsin ZT-3, comprising the amino acid sequence according to SEQ ID NO: 4; and trypsin ZT-4, comprising the amino acid sequence according to SEQ ID NO: 5, or an amino acid sequence having 80% or more sequence homology thereto. Also included are amino acid sequences having 80% or more sequence homology to the amino acid sequences set forth in SEQ ID NOs: 2-5. Typically, such sequence homology is 85, 90, 95 or 99% homologous to the amino acid sequences of SEQ ID NOs: 2-5.
[0074] In one aspect of the present invention, a composition is provided, comprising at least one cod trypsin ZT isoform according to the present invention and suitable excipients and carriers. The cod trypsin ZT isoform may be selected from cod trypsin ZT-1, comprising an amino acid sequence according to SEQ ID NO: 2; cod trypsin ZT-2, comprising an amino acid sequence according to SEQ ID NO: 3; cod trypsin ZT-3, comprising an amino acid sequence according to SEQ ID NO: 4; and cod trypsin ZT-4, comprising an amino acid sequence according to SEQ ID NO: 5. Also included are amino acid sequences having a sequence homology of 80% or more to the amino acid sequences set forth in SEQ ID NOs: 2-5. Typically, such sequence homology is 85, 90, 95 or 99% homologous to the amino acid sequences of SEQ ID NOs: 2-5.
[0075] Typically, the composition comprises a mixture of the codfish trypsin ZT isoform with other codfish trypsins. Preferably, the codfish trypsin ZT isoform comprises at least 5% (w / w) of the total codfish trypsin content in the composition, such as at least 10, 15, 20, 25, 30, 35, 40, 45 or 50% or more (w / w) of the total codfish trypsin content in the composition.
[0076] The composition is typically administered topically in the form of a lotion, hydrogel, oral spray or nasal spray. The composition may further comprise a polyvalent alcohol, such as glycerol.
[0077] In one embodiment of this aspect, the composition is provided for use in therapy.
[0078] In one embodiment of this aspect, the composition is provided for use in treating or preventing a disease caused by a pathogenic organism selected from the group consisting of viruses, bacteria, fungi, parasites, and protozoa.
[0079] In one embodiment of this aspect, the composition is provided for use in treating or preventing upper respiratory tract diseases caused by pathogenic organisms such as viruses, bacteria, and fungi.
[0080] In one embodiment of this aspect, the composition is provided for use in treating or preventing pain; acute inflammation; chronic inflammation; arthritis; joint inflammation; bursitis; osteoarthritis; rheumatoid arthritis; juvenile rheumatoid arthritis; septic arthritis; fibromyalgia; systemic lupus erythematosus; phlebitis; tendinitis; rash; psoriasis; acne; eczema; seborrheic eczema on the face; eczema on the hands, face or neck; foreskin infection; tinea pedis; fistula infection; local ulcer infection; umbilical infection in newborns; wrinkles; scars; keloids; furuncle; warts and allergic itching; hemorrhoids; fungal infections and immune disorders, including autoimmune diseases.
[0081] In one embodiment of this aspect, the composition is provided for use in treating wound infections and burn wounds.
[0082] In one embodiment of this aspect, the composition is provided for use in removing necrotic or desquamated skin from otherwise healthy skin.
[0083] In one embodiment of this aspect, the composition is provided for cosmetic use.The composition may further comprise other cosmetically active compounds.
[0084] In one aspect of the present invention, there is provided a method for treating a disease, comprising administering a therapeutically effective amount of a composition according to the present invention to a patient in need thereof.
[0085] In one embodiment of this aspect, the disease is caused by a pathogenic organism selected from the group consisting of viruses, bacteria, fungi, parasites, and protozoa.
[0086] In one embodiment of this aspect, the disease is an upper respiratory tract disease caused by pathogenic organisms such as viruses and bacteria.
[0087] In one embodiment of this aspect, the disease is selected from pain; acute inflammation; chronic inflammation; arthritis; joint inflammation; bursitis; osteoarthritis; rheumatoid arthritis; juvenile rheumatoid arthritis; septic arthritis; fibromyalgia; systemic lupus erythematosus; phlebitis; tendinitis; rash; psoriasis; acne; eczema; seborrheic eczema on the face; eczema on the hands, face or neck; foreskin infection; tinea pedis; fistula infection; local ulcer infection; umbilical infection in newborns; wrinkles; scars; keloids; furuncle; warts and allergic itching; hemorrhoids; fungal infections and immune disorders, including autoimmune diseases.
[0088] In one embodiment of this aspect, the disease is a wound infection or a burn wound.
[0089] In one aspect of the present invention, isolated cod trypsin ZT isoforms are provided, selected from full-length trypsin ZT-1, which comprises the amino acid sequence according to SEQ ID NO: 19; full-length trypsin ZT-2, which comprises the amino acid sequence according to SEQ ID NO: 20; full-length trypsin ZT-3, which comprises the amino acid sequence according to SEQ ID NO: 21; and full-length trypsin ZT-4, which comprises the amino acid sequence according to SEQ ID NO: 22.
[0090] In one aspect of the present invention, there is provided a method for preparing a cod trypsin ZT isoform comprising an amino acid sequence according to any one of SEQ ID NO: 2 to SEQ ID NO: 5, comprising
[0091] (i) Trypsin ZT was extracted from cod viscera,
[0092] (ii) subjecting the extract to at least one or more chromatography steps, including an affinity chromatography step using a p-aminobenzamidine affinity ligand, and
[0093] (iii) Desorption and elution of cod trypsin ZT isoform bound to the p-aminobenzamidine affinity ligand.
[0094] In one embodiment of this aspect, the method further comprises at least one step using an anion exchange resin after the affinity chromatography step (ii).
[0095] In one embodiment of this aspect, the cod trypsin ZT isoform is selected from trypsin ZT-1, which comprises the amino acid sequence according to SEQ ID NO: 2; trypsin ZT-2, which comprises the amino acid sequence according to SEQ ID NO: 3; trypsin ZT-3, which comprises the amino acid sequence according to SEQ ID NO: 4; and trypsin ZT-4, which comprises the amino acid sequence according to SEQ ID NO: 5, or a mixture thereof.
[0096] Cod viscera are commonly used to purify and isolate trypsin ZT isoforms. The inventors have discovered a novel process described below that is suitable for commercial scale production of trypsin ZT isoforms. The extraction is performed at a temperature below 10°C at pH 6-8. The cod viscera are mixed with water in a ratio of 1:6 to 1:20 (w / w). The extract is separated from the residual water and further clarified by precipitation and filtration. Microfiltration and ultrafiltration are then performed to produce a solution containing trypsin ZT isoforms, which is used for chromatographic separation which may include several steps.
[0097] Affinity chromatography is performed, preferably by aminobenzamidine affinity chromatography, to purify the trypsin ZT isoform. The trypsin ZT isoform can then be further purified by anion exchange chromatography.
[0098] One method of using a trypsin ZT isoform or a mixture of purified cod fish trypsin containing a trypsin ZT isoform is in a formulation containing 0 to 90% (vol / vol) of a polyvalent alcohol (polyol) such as glycerol and water. Suitable concentrations of the trypsin ZT isoform are at least 1 to 100 protein concentration ratios (relative to other trypsin forms), preferably 5% or more (w / w) of the total cod fish trypsin content. For CBZ-Gly-Pro-Arg-pNA (benzyloxycarbonyl Gly-Pro-Arg-p-nitroanilide), the trypsin activity is 0.1 to 10,000 enzyme activity units per 100 ml of the final hydrogel / lotion formulation.
[0099] The present invention further provides (a) methods related to certain conditions using an effective amount of the purified trypsin ZT isoforms described above, (b) compositions or materials for use in such methods, (c) pharmaceutical or medical device compositions containing an effective amount of a trypsin ZT isoform for use in such methods, and (d) the use of enzymes or enzyme compositions in the manufacture of medicaments (pharmaceuticals and medical devices) for use in such methods.
[0100] The method is particularly useful for:
[0101] Treatment or prevention of pathogenic diseases caused by viruses, bacteria and fungi, which reside, for example, in the upper respiratory tract, lower respiratory tract and lungs;
[0102] Treatment or prophylactic prevention of skin conditions, such as, for example, acne, rash, psoriasis or eczema, including seborrheic eczema on the face or eczema on the hands, face, scalp or neck, hemorrhoids, etc., wherein the amount of the trypsin ZT isoform and other trypsin administered is preferably an effective amount for the treatment or prevention of the skin condition;
[0103] Treatment of lung diseases, wherein the trypsin ZT isoform and other trypsin (or the absence of other trypsin) are administered in therapeutically effective amounts, for example in the form of a pressurized metered-dose high-efficiency inhaler;
[0104] Treatment or prophylactic prevention of wound infection and wound debridement by administering to the wound a microbial infection preventing effective amount of a trypsin ZT isoform with or without other trypsin enzymes, or by administering a microbial inhibitory effective amount of a trypsin ZT isoform with or without other trypsin enzymes to enhance wound healing, when the wound being treated may be substantially free of necrotic tissue; treatment of burns, wherein preferably the amount of a trypsin ZT isoform administered with or without other trypsin enzymes is an amount sufficient to promote healing;
[0105] Treatment, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably an amount sufficient to promote healing;
[0106] Treatment of radiation burns, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably an amount sufficient to promote healing;
[0107] Removing necrotic or desquamated skin from otherwise healthy skin to improve the appearance of the skin, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably an amount sufficient to promote healing;
[0108] Treating cracked heels, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably an amount sufficient to promote healing;
[0109] for use in the management of irritated skin, such as dry patches, itching, redness and blemishes, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably an amount sufficient to promote healing;
[0110] Treatment or prophylactic prevention of cystic fibrosis, cancer (e.g., by administering a tumor therapeutically effective amount or a tumor metastasis preventing or inhibiting amount of a trypsin ZT isoform), atherosclerosis, asthma, septic shock, toxic shock syndrome, tissue adhesions (e.g., tendon sheath, abdominal surgery or joint adhesions), reperfusion injury, malaria, immune disorders (e.g., autoimmune diseases), apoptosis, colitis and enteritis (e.g., Crohn's disease), wherein preferably the amount of trypsin ZT isoforms and related peptidases administered is effective;
[0111] Treatment or prophylactic prevention of microbial infections, e.g., viral infections, such as rhinovirus (RV), respiratory syncytial virus (RSV), influenza, herpes virus infections (e.g., HSV-1, HSV-2, herpes zoster or genital herpes infections), HIV, hepatitis, coronavirus, cytomegalovirus or papillomavirus infections; infections causing gastrointestinal diseases, such as ulcers or diarrhea; fungal infections, such as systemic, skin, oral, vaginal or esophageal fungal infections, including, for example, yeast infections, including nail fungal infections and Candida infections; ocular microbial infections, preferably treated with ocular administration; bacterial infections, including those caused by Helicobacter pylori, Staphylococcus spp., Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Haemophilus influenzae (Haemophilus influenza), Streptococcus mitis, Streptococcus spp., Klebsiella spp., Pseudomonas spp., Neisseria gonorrheae, Haemophilus spp., Chlamydia spp., syphilis and E. coli infections, and bacterial infections causing chancroid; opportunistic microbial infections in immunocompromised patients, wherein the amount of cod fish trypsin administered is preferably an effective amount for the treatment or prevention of microbial infections, or has an inhibitory activity against cell-cell or cell-virus adhesion;
[0112] Treatment or prophylactic prevention of an indication selected from the group consisting of pain, inflammation, acute or chronic inflammation, arthritis, joint inflammation, bursitis, osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, septic arthritis, muscular pain, systemic lupus erythematosus and phlebitis, wherein the preferred amount is a therapeutically or prophylactically effective amount;
[0113] removing dental plaque, wherein the amount of the trypsin ZT isoform administered with or without other trypsin is preferably a plaque removal effective amount; and dissolving blood clots, wherein the amount of the trypsin ZT isoform is preferably a clot dissolving effective amount.
[0114] The method comprises administering a composition comprising a trypsin ZT isoform as described above.
[0115] The present invention provides topical cosmetic and medical compositions comprising the above-mentioned trypsin ZT isoform; and a gel, cream or suppository composition.
[0116] The present invention further provides methods for inhibiting or prophylactically preventing infection by pathogenic microorganisms by administering a trypsin ZT isoform with or without other trypsin enzymes. Preferably, trypsin ZT is administered, with or without other trypsin enzymes, to a body part containing the primary infection pathway for the microorganism in question. In one embodiment, a spray, ointment or wash is applied to a body orifice involved in sexual activity, e.g., to prevent HIV or hepatitis infection. In another embodiment, a trypsin ZT isoform or a related peptidase is administered to the upper airway, e.g., via an aerosol, to inhibit or prevent infection by common cold viruses such as rhinovirus or coronavirus.
[0117] Methods of treating cellular tissues, body fluids or compositions in vitro to remove cell adhesion components can reduce immune rejection of cellular tissues, body fluids or compositions transplanted from one individual to another individual. In another aspect, such treatment removes or inactivates cell adhesion components found in the treated tissues, body fluids or compositions of cells involved in microbial infection.
[0118] When treating or prophylactically preventing septic shock or toxic shock syndrome by administering a trypsin ZT isoform or related peptidase, suitable routes of administration include systemic administration. For vaginal infections associated with shock, vaginal douches, creams, gels or suppositories may be used as a method of administration.
[0119] When administering a trypsin ZT isoform or related peptidase to treat or prophylactically prevent pain, inflammation, acute or chronic inflammation, arthritis, joint inflammation, bursitis, osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, septic arthritis, muscular pain, systemic lupus erythematosus, phlebitis, suitable routes of administration include (but are not limited to) creams, gels or suppositories, especially (but not limited to) hydrogels containing glycerol or other polyols.
[0120] When treating or prophylactically preventing rash; psoriasis; acne; eczema, including seborrheic eczema of the face or eczema of the hands, face or neck; foreskin infections; tinea pedis; fistula infections; local ulcer infections; umbilical infections in neonates; wrinkles; scars and keloids; boils; warts and allergic itching; hemorrhoids, etc.; wounds; wound infections; burn wounds; removal of necrotic or desquamated skin from otherwise healthy skin to improve skin appearance; fungal infections, such as systemic, cutaneous, oral, vaginal or esophageal fungi, including, for example, yeast infections, including nail fungal infections and Candida infections; and immune disorders, including autoimmune diseases, suitable routes of administration include creams, gels or suppositories, especially (but not limited to) hydrogels containing glycerol or other polyols.
[0121] The above objects are obtained by using a composition containing an effective amount of a trypsin ZT isoform and (or without) other trypsin enzymes, which is capable of relieving pain, inflammation, arthritis, swelling, edema, psoriatic eczema, dermatitis, rash and / or other symptoms of the diseases mentioned in the introduction. The trypsin ZT isoform can be obtained from cod viscera in high yields and in a relatively simple manner. It has been found that the trypsin ZT isoform can be purified on a commercial scale in a relatively simple manner with reasonable yields. The trypsin ZT isoform alone or together with other Atlantic serine proteases can be used for the purposes of the present invention.
[0122] The trypsin ZT isoforms presented in the present disclosure can be desorbed from the affinity matrix by applying conditions that will destabilize the interaction between the enzyme and the affinity ligand. Such conditions include high salt followed by low pH, preferably in 30% or more glycerol. After the acid elution step, the column eluent is flowed into a neutralizing buffer to stabilize the codfish trypsin. The trypsin ZT isoforms can then be further purified using anion exchange and eluted at increasing salt concentrations. By these methods, trypsin ZT isoforms can be isolated with a purity of more than about 90%. Thus, the resulting codfish trypsin fraction contains 2-3 major isoforms, as demonstrated by SDS electrophoresis (which produces two color bands) and MALDI-TOF mass spectrometry analysis. The molecular weight of the trypsin ZT isoforms is about 25 kDa, and the calculated isoelectric points are 4.35-4.49, depending on the isoform.
[0123] Depending on the intended use, the trypsin ZT isoforms in the form of specific formulations with or without other trypsins can be used as medicaments, in medical devices such as chemical formulations, or in cosmetics. The trypsin ZT isoforms of the present invention (with or without other trypsins) are administered topically, orally, rectally, vaginally, by instillation (e.g., into the urethra or fistula), by the pulmonary route (e.g., by using an aerosol (e.g., by using a pressurized metered dose inhaler (pMDI))), by applying drops to the eye, or systemically, such as parenterally, including, for example, intramuscularly, subcutaneously, intraperitoneally, intraarterially, or intravenously. According to standard pharmaceutical practice, the trypsin ZT isoforms are administered in solution or in combination with a pharmaceutically acceptable carrier or excipient. For oral administration modes, the trypsin ZT isoforms are used in the form of tablets, capsules, buccal tablets, chewable tablets, dragees, powders, syrups, elixirs, aqueous solutions and suspensions. For parenteral administration, a sterile solution of the trypsin ZT isoform is typically prepared and the pH of the solution is appropriately adjusted and buffered. For intravenous use, the total concentration of the solute should be controlled to render the preparation isotonic. For ocular administration, the ointment or instillable liquid may be delivered by an ocular delivery system known in the art, such as an applicator or eye dropper. For pulmonary administration, a suitable diluent and / or carrier will be selected to allow for the formation of an aerosol. For topical administration, the trypsin ZT isoform is typically administered in the form of a hydrogel containing 0 to 85% glycerol, such as about 20% to 30% glycerol and possibly up to 85% glycerol.
[0124] For topical treatment, a suitable dose of the trypsin ZT isoform per application with or without other trypsin is about 0.01 μg / cm 2 To about 1mg / cm 2 , preferably about 0.1 μg / cm 2 To about 0.01mg / cm 2In some embodiments, the amount of trypsin ZT isoform administered is generally within the range of about 0.1 mg / 100 ml to about 100 mg / 100 ml (using, for example, about 0.01 mg / ml enzyme gel). For systemic treatment, the dosage will generally be selected to maintain serum levels of the trypsin ZT isoform between about 0.1 mg / 100 ml and about 100 mg / 100 ml, preferably between about 0.5 mg / 100 ml and about 2.0 mg / 100 ml, with or without other trypsin enzymes. In an alternative measure of preferred systemic administration, preferably about 0.1 mg / kg to about 10 mg / kg, more preferably about 1 mg / kg, will be used. For vaginal and urethral treatments, suitable irrigation / drip solutions of the trypsin ZT isoform will generally have a concentration of about 1 μg / ml to about 15 mg / ml, preferably about 100 μg / ml to about 3 mg / ml. For all treatments, the enzyme composition will generally be administered about 1 to about 10 times per day, preferably about 2 to about 5 times per day. Of course, these values will vary depending on many factors, including the type and severity of the disease, and the age, weight and medical condition of the patient, as will be recognized by those skilled in the art of medical technology. It is believed that significantly higher doses may be used without significant adverse effects.
[0125] For wound healing, it is preferred to apply the trypsin ZT isoform (with or without other trypsins) more frequently than when it is only applied when the wound is first dressed. Preferably, the trypsin ZT isoform is applied at least about every time the wound dressing is changed. The trypsin ZT isoform may also be applied at least about every other day, more preferably every day or several times a day. For skin conditions, such as eczema, psoriasis, etc., it is preferred to apply the trypsin ZT isoform (with or without other trypsins) hydrogel every day, more preferably twice a day. For acute or chronic inflammation, arthritis, joint inflammation, bursitis, osteoarthritis, etc., it is preferred to apply the trypsin ZT isoform every day, more preferably twice a day.
[0126] Many methods for determining the percentage of protein homology are known in the art. When performing sequence alignments, ClustalW2 (Clustal 2.1 version) is used to calculate the percentage of identity (EMBL-EBI website http: / / www.ebi.ac.uk / Tools / msa / clustalw2 / date 4th of May 2015).
[0127] The invention will now be described by way of a number of non-limiting examples.
[0128] Example 1.
[0129] Preparation of protease mixture from cod
[0130] About 100 kg of frozen Atlantic cod viscera were thawed and added to four volumes of cold drinking water in an extraction tank, and the pH was adjusted to about pH 6 with sodium hydroxide solution. The mixture was stirred at 0 to 5°C for about 10 hours. After a short period of crude material precipitation (about 30 minutes), the aqueous extract was removed from the remaining insoluble viscera with a pump and collected in a precipitation tank. The aqueous extract was allowed to stand in a cooled precipitation tank to precipitate for about 40 to 80 hours. The supernatant was decanted from the supernatant tank to a storage tank using a pump. The supernatant was concentrated 10 to 20 times by ultrafiltration and diafiltration to an acceptable ionic strength level, wherein the conductivity was less than about 2.5 mS / cm. About 10-15 liters of ultrafiltered and diafiltered protein concentrate were obtained.
[0131] Example 2.
[0132] Purification of cod trypsin ZT isoforms from concentrated cod viscera extracts About 12 liters of the ultrafiltered and diafiltered concentrate obtained as in Example 1 were applied to sequential, serially connected, approximately 1 liter packed chromatography columns, the first column containing carboxymethyl (CM) fast flow cation exchange resin (GE healthcare) and the second column containing p-aminobenzamidine affinity ligand coupled to agarose resin (GE healthcare). The CM and p-aminobenzamidine columns were pre-equilibrated with approximately 10 column volumes of 25 mM Tris buffer (pH 7.8) containing 2.5 mM calcium chloride (buffer A). The concentrate was pumped onto the CM and p-aminobenzamidine columns at a flow rate of approximately 100 ml per minute. When application of the concentrated solution to the columns was complete, residual material was washed from the sequential column system with approximately 8 liters of buffer A. After this wash was completed, the p-aminobenzamidine affinity column was disconnected from the CM column and washed with a high salt solution of 25 mM Tris buffer (pH 7.5) containing 0.5 M NaCl and 2.5 mM calcium chloride in approximately 5 column volumes. Next, codfish trypsin was desorbed from the affinity ligand and eluted from the column with an acid solution of 25 mM acetic acid (pH 3.2) containing 10 mM calcium chloride and 30% glycerol.
[0133] The purified preparation containing codfish trypsin ZT isoform was found to be homogeneous by SDS PAGE electrophoresis. The purified preparation was filter sterilized through a 0.22 micron filter and stored frozen at about -20°C. The preparation containing codfish trypsin ZT isoform was filter sterilized through a 0.22 micron filter and stored frozen at about -20°C. The preparation containing codfish trypsin ZT isoform was applied to an anion exchange chromatography column (MonoQ) and the protein was eluted with a salt gradient ( Figure 1The column was equilibrated with buffer (20 mM Tris, 10 mM CaCl2, pH 8.0) and the enzyme was eluted with a linear 0-150 mM NaCl gradient at 40 column volumes, a linear 150-620 mM NaCl at 6 column volumes, and a 620-850 mM NaCl at 10 column volumes at a flow rate of 1 mL / min. Figure 1 The peak of the protein labeled with trypsin ZT was subjected to SDS-PAGE analysis ( Figure 2 ). The protein band on the gel from the trypsin ZT peak was separated from the gel and analyzed using matrix-assisted laser desorption / ionization time-of-flight mass spectrometry (MALDI-TOF MS). Mass spectrometry (MS) analysis showed identity with trypsin ZT-1, trypsin ZT-2, trypsin ZT-3, and trypsin ZT-4 (Tables 1 and 2). Antibodies to trypsin I and trypsin X were prepared in rabbits against a peptide ((NH2-)CVLSGWVRDTMA(-COOH)) (SEQ ID NO: 23) corresponding to residues 228-239 at the farthest C-terminus of codfish trypsin I and codfish trypsin X. Antibodies were affinity purified from rabbit serum using the peptide coupled to the gel bead load. Polyclonal antibodies to trypsin ZT isoforms were prepared in mouse ascites fluid as described in Overkamp et al. (Overkamp, Mohammed-Ali et al., 1988, J Immunoassay 9: 51-68). Purified forms of recombinant trypsin ZT-4 were injected intraperitoneally (ip) into Balb / C2 mice. Mice were sacrificed on day 34 and ascites fluid was collected. Western blot analysis was performed using the respective antibodies. Figure 1 The peaks of trypsin ZT were analyzed by Western blot ( Figure 3 ). The trypsin ZT isoform antibody reacts against proteins from the peak-labeled trypsin ZT, whereas antibodies against trypsin I and trypsin X do not react ( Figure 3 ).
[0134] Table 1 shows the Figure 2 Peptide masses obtained by MS analysis of protein bands from SDS-PAGE gels in (non-guanidated samples), see column 1 Mr (experimental). Mr indicates relative molecular weight (Da). Columns 2, 3 and 4 show calculated values from in silico tryptic digests of amino acid sequences Trypsin ZT-1, Trypsin ZT-2, Trypsin ZT-3 and Trypsin ZT-4 (masses matching masses in column 1). Column 5 shows the sequences of peptides that generated mass values from in silico tryptic digests. Column 6 shows modifications of different peptides based on in silico tryptic digests.
[0135] Table 1.
[0136]
[0137] The sequences in Table 1 are as follows:
[0138] Seq ID NO Amino acid sequence SEQ ID NO 6 IIGGQDCEPR SEQ ID NO 7 VFEGTEQLVK SEQ ID NO 8 LQCLDVPIVEPVACQASYPGMISPR SEQ ID NO 8 LQCLDVPIVEPMACQASYPGMISPR SEQ ID NO 8 LQCLDVPIVEPVACQASYPGMISPR SEQ ID NO 9 LQCLDVPIVETVDCEAAYPGMISPR SEQ ID NO 10 MVCAGYMDGGR SEQ ID NO 11 MMCVGFMDGGR SEQ ID NO 10 MVCAGYMDGGR SEQ ID NO 11 MMCVGFMDGGR SEQ ID NO 12 GCAEPNSPGVYVK SEQ ID NO 12 GCAEPNSPGVYVK
[0139] Table 2 shows the Figure 2 Peptide masses obtained from MS analysis of protein bands from the SDS-PAGE gel in (guanidated samples), see column 1 Mr (experimental). Mr indicates relative molecular weight (Da). Columns 2, 3 and 4 show calculated values from in silico tryptic digests of the amino acid sequences of Trypsin ZT-1, Trypsin ZT-2, Trypsin ZT-3 and Trypsin ZT-4 (masses matching the masses in column 1). Column 5 shows the sequences of peptides that generated mass values from the in silico tryptic digests. Column 6 shows modifications of different peptides based on the in silico tryptic digests.
[0140] Table 2.
[0141]
[0142] The sequence in Table 2 is as follows:
[0143] Seq ID No Amino acid sequence SEQ ID NO 6 IIGGQDCEPR SEQ ID NO 7 VFEGTEQLVK SEQ ID NO 9 LQCLDVPIVETVDCEAAYPGMISPR SEQ ID NO 8 LQCLDVPIVEPVACQASYPGMISPR SEQ ID NO 8 LQCLDVPIVEPVACQASYPGMISPR SEQ ID NO 8 LQCLDVPIVEPVACQASYPGMISPR SEQ ID NO 9 LQCLDVPIVETVDCEAAYPGMISPR SEQ ID NO 9 LQCLDVPIVETVDCEAAYPGMISPR SEQ ID NO 10 MVCAGYMDGGR SEQ ID NO 11 MMCVGFMDGGR SEQ ID NO 11 MMCVGFMDGGR SEQ ID NO 13 DVCNGDSGSPLVCEGVLTGLVSWGR SEQ ID NO 13 DVCNGDSGSPLVCEGVLTGLVSWGR
[0144] Example 3.
[0145] Multivariate Substrate Distribution of Trypsin ZT Isoforms
[0146] The substrate specificity of enzymes (proteases) is analyzed using multivariate substrate profiling (O'Donoghue, Eroy-Reveles et al., 2012, Nature Methods 9: 1095-1100). Proteases can cleave substrates at different amino residues within the peptide sequence, indicating differences in substrate specificity. Trypsin is designated by its preference for cleaving the C-terminus to either arginine or lysine residues.
[0147] Enzyme isoforms
[0148] Codfish trypsin isomerase was separated by applying benzamidine purified codfish trypsin to a MonoQ HR 5 / 5 ion exchange column. For the separation of trypsin I, the column was equilibrated with 20 mM Tris, 5 mM ethanolamine, 10 mM CaCl2, pH 9.1, and the enzyme was eluted with a linear 0-200 mM NaCl gradient at 80 column volumes and a linear 200-1000 mM NaCl gradient at 10 column volumes at a flow rate of 1 mL / min. Prior to application, the sample pH was adjusted to pH 9.1 with 1 M NaOH.
[0149] For separation of trypsin ZT isoforms, the column was equilibrated with 25 mM Tris, 25 mM CaCl2, 15% (v / v) glycerol, pH 7.5, and the enzyme was eluted with a linear 0-150 mM NaCl gradient at 5 column volumes, a linear 150-550 NaCl gradient at 20 column volumes, and a linear 500-1000 mM NaCl gradient at 1 column volume at a flow rate of 1 mL / min.
[0150] The composition of both enzyme samples (Trypsin ZT and Trypsin I) was adjusted so that the final concentration of Tris was 60 mM, the final concentration of CaCl2 was 30 mM and the final concentration of glycerol was 15% (v / v), with a pH value of 8.5.
[0151] Multivariate Substrate Distribution Analysis
[0152] Purified trypsin ZT isoforms or trypsin I were incubated with a peptide library with broad physiochemical diversity (124 defined peptides, 14-mer sequence, 1612 peptide bonds in total) (5, 15 and 60 minutes) as described in O'Donoghue, Eroy-Reveles et al. (O'Donoghue, Eroy-Reveles et al., 2012, Nature Methods 9: 1095-1100). After incubation, cleavage sites were identified by mass spectrometry analysis (O'Donoghue, Eroy-Reveles et al., 2012, Nature Methods 9: 1095-1100).
[0153] result
[0154] Multivariate substrate distribution analysis unexpectedly revealed a large number of cleavage sites unique to the trypsin ZT isoform compared to the trypsin I disclosed in WO 2000078332 ( Figure 4and Table 4). Furthermore, cleavage sites that showed preferential cleavage by the trypsin ZT isoform compared to trypsin I were identified (Table 4). Based on the results from the multivariate substrate distribution analysis, a table containing values based on the ratio of standard scores (Z scores) at the P4-P4′ positions in the substrate was generated, in which the substrate specificity of trypsin ZT and trypsin I was compared (Table 3). Positive values (Z scores) reflect a preference for amino acid residues in a certain P position that favors the trypsin ZT isoform compared to trypsin I. Surprisingly, the multivariate substrate distribution on the trypsin ZT isoforms indicated that amino acids surrounding arginine or lysine in the substrate had different effects on their cleavage compared to trypsin I.
[0155] Table 3 Shown is a comparison of the substrate specificity of trypsin ZT and trypsin I based on the values of the ratio of the standard scores (Z scores) at the P4-P4' positions in the substrate after 5, 15 and 60 minutes of incubation. The amino acid residues in the substrate that undergo cleavage are designated P1, P2, P3, P4 in the N-terminal direction from the start of cleavage (Schechter and Berger, 1967, Biochem Biophys Res Commun 27: 157-162, Schechter and Berger, 1968, Biochem Biophys Res Commun 32: 898-902). The residues in the C-terminal direction are designated P1', P2', P3', P4'. The P positions are provided in the column and each row shows the amino acid in a different P position. A positive value (Z score) in the table reflects a preference for an amino acid residue in a certain P position in favor of the trypsin ZT isoform compared to trypsin I. Negative values (Z-scores) reflect a preference in favor of trypsin I compared to trypsin ZT. For example, based on the values from Table 3, it can be seen that trypsin ZT is significantly better suited to cleaving peptides containing several consecutive positively charged residues (arginine or lysine) than trypsin I. Moreover, these types of sequences, i.e., amino acid sequences rich in lysine and arginine, are often found in protein toxins, proteins and peptides involved in pathogenesis (Suzuki, Orba et al., 2010, PLoS Pathogens 6:e1000801, Fentress, Steinfeldt et al., 2012, Cell Microbiol. 14:1921-1933, Jiang, Cun et al., 2012, J. Virol. 86:7256-7267, Milletti, 2012, Drug Discovery Today 17:850-860, Gallaher and Garry, 2015, Viruses 7:285-305). As mentioned previously, the trypsin ZT isoform therefore has advantageous properties against proteins that are responsible for the pathogenicity of many microorganisms.
[0156] Table 3.
[0157]
[0158] Table 3 continued.
[0159]
[0160] Table 3 continued.
[0161]
[0162] Table 4 Precursor ion intensity of selected peptides from multivariate distribution is shown after incubation with trypsin ZT or trypsin I. Precursor ion intensity is the peptide peak intensity (MS) before fragmentation, which represents the measured value of the relative abundance of a given species. The X in the peptide sequence represents a placeholder, which represents an amino acid not present in the peptide sequence. The data show that trypsin ZT isoforms are uniquely capable of cleaving three peptide sequences (QGKKAPXX, WGNRSPLE, and QAVRPNGM) compared to trypsin I. In addition, the data show that trypsin ZT isoforms preferentially cleave two peptides compared to trypsin I. Trypsin ZT isoforms are capable of cleaving XIARQPWN within 5 minutes and FDNRVGKW within 15 minutes, while in the case of trypsin I, cleavage in these two peptides is detected only after incubation for 60 minutes.
[0163] Table 4.
[0164]
[0165] Example 4.
[0166] Purification of cod trypsin ZT isoforms from concentrated cod visceral extracts
[0167] About 12 liters of the ultrafiltered and diafiltered concentrate obtained as in Example 1 were applied to about 1 liter packed chromatography columns connected in series, the first column containing CM fast flow cation exchange resin (GE healthcare), the second column containing p-aminobenzamidine affinity ligand coupled to agarose resin (GE healthcare), and the third column containing DEAE fast flow anion exchange resin (GE healthcare). The CM and p-aminobenzamidine columns were previously equilibrated with about 10 column volumes of 25 mM Tris buffer (pH 7.8) containing 2.5 mM calcium chloride. The concentrate was pumped onto the CM and p-aminobenzamidine columns at a flow rate of about 100 ml per minute. When the application of the concentrated solution to the columns was completed, residual material was washed out from the continuous column system with about 8 liters of buffer A. After this wash is complete, the p-aminobenzamidine affinity column is disconnected from the CM column and washed with a high salt solution of 25 mM Tris buffer (pH 7.5) containing 0.5 M NaCl and 2.5 mM calcium chloride in about 5 column volumes. Next, codfish trypsin is desorbed from the affinity ligand and eluted from the column with an acid solution of 25 mM acetic acid (pH 3.2) containing 10 mM calcium chloride and 30% glycerol. The codfish trypsin fraction is collected in a neutralization buffer of 200 mM Tris (pH 8.5) containing 30% glycerol. The DEAE anion exchange column is pre-equilibrated with about 10 column volumes of 25 mM Tris buffer (pH 7.8) containing 2.5 mM calcium chloride. The codfish trypsin fraction is applied to the DEAE anion exchange resin and washed with about 5 column volumes of the equilibration buffer. Next, the trypsin ZT isoform was desorbed from the column using a gradient salt solution up to 0.9 M NaCl. The purified cod trypsin ZT isoform preparation was found to be homogeneous by SDS PAGE electrophoresis and FPLC Mono Q chromatography. The purified preparation was filter sterilized through a 0.22 micron filter and stored frozen at approximately -20°C.
[0168] Example 5.
[0169] Preparation of hydrogel formulations of cod trypsin including cod trypsin ZT isoforms
[0170] The formulation containing the purified cod fish trypsin ZT isoform of Example 2 was mixed with a hydrocolloid gel comprising an aqueous gel containing 0.8% w / v Carbomer 940 and 40% glycerol. A final concentration of 4 enzyme units (U / mg) per mg of the final gel-enzyme mixture (enzyme hydrogel ointment) was obtained at a 1:1 ratio of cod fish trypsin formulation to hydrogel, the enzyme units being determined as previously described using Cbz-GPR-pNA as the substrate. Thus, the resulting enzyme hydrogel ointment contained approximately 0.01 mg / ml, or 1 U / ml, of cod fish trypsin enzyme, 0.4% Carbomer 940, 20% glycerol, and 0.04% parabens.
[0171] Example 6.
[0172] Antiviral activity of trypsin ZT isoforms against enterovirus as a rhinovirus model
[0173] Picornaviruses are small single-stranded positive sense RNA viruses that do not contain a lipid envelope. Enteroviruses and rhinoviruses are two genera of the Picornaviridae family. Enteroviruses initially replicate in the oropharynx and survive in the acidic environment of the stomach. The small intestine is the main invasion site of enteroviruses. Rhinoviruses replicate in the nasal passages, but are destroyed in the acidic environment of the stomach. Rhinoviruses and enteroviruses have the same morphology, but can be distinguished based on clinical, biophysical and epidemiological studies. There are problems with operating rhinoviruses in cell culture (Racaniello, 2007, Fields virology, 5th edition, 795-838). Therefore, enteroviruses are used as models of rhinoviruses to analyze the antiviral properties of trypsin ZT isoforms.
[0174] Materials and methods
[0175] Enterovirus stock solution
[0176] Enterovirus (Coxsackievirus B2) was isolated from patients at the University Hospital of Iceland, department of Virology and grown in MA-104 cells (African green monkey kidney cells) or Vero cells (African green monkey kidney cells). Coxsackievirus B2 was titrated according to the Reed-Muench method (REED and MUENCH, 1938, American Journal of Epidemiology 27: 493-497) (TCID 50 =8,23).
[0177] Enzyme isoforms
[0178] Codfish trypsin isomerase was separated by applying benzamidine purified codfish trypsin to a MonoQ HR 5 / 5 ion exchange column. For separation of trypsin ZT isoforms, the column was equilibrated with 25 mM Tris, 25 mM CaCl2, pH 7.5, and the enzyme was eluted with a linear 0-400 mM NaCl gradient in 5 column volumes and a linear 400-1000 mM NaCl in 20 column volumes at a flow rate of 1 mL / min.
[0179] deal with
[0180] MA-104 cells were grown to 95% confluence in 96-well microtiter plates. Enterovirus was diluted to 10% from stock solution using minimum essential medium (MEM). -6 , and 1.5mL of diluted solution is placed in two different vials. The vials are treated with 1.5mL of trypsin ZT isoform and 1.5mL of MEM as a positive control. The negative control is virus-free MEM (3mL). All vials are cultivated for 90 minutes at 34°C and 5% CO2, followed by the addition of 100 μL of benzamidine agarose solution to remove residual trypsin and cultivate for another 30 minutes. The solution is centrifuged at 5500rpm for 3 minutes, and then 2mL of supernatant is placed in Eppendorf vials (Eppendorf vial). 200 μL of solution is placed in each well, a total of 10 wells in a microtiter plate. Cultivate the plate for 30 minutes. After cultivation, the culture medium is discarded and MEM with 1% newborn calf serum (NCS) is added to all wells. Use a microscope to monitor whether there is infection.
[0181] result
[0182] Trypsin ZT isoforms were highly effective as antiviral agents against enterovirus (Coxsackievirus B2) used as a model for rhinovirus. Figure 5 middle.
[0183] The present invention also relates to the following embodiments (which correspond to the claims of the original application):
[0184] 1. An isolated cod trypsin ZT isoform comprising the amino acid sequence according to SEQ ID NO: 1, or an amino acid sequence having 80% or higher sequence homology with said amino acid sequence.
[0185] 2. The isolated cod trypsin ZT isoform according to embodiment 1, selected from cod trypsin ZT-1, comprising the amino acid sequence according to SEQ ID NO: 2; cod trypsin ZT-2, comprising the amino acid sequence according to SEQ ID NO: 3; cod trypsin ZT-3, comprising the amino acid sequence according to SEQ ID NO: 4; and cod trypsin ZT-4, comprising the amino acid sequence according to SEQ ID NO: 5, or amino acid sequences having 80% or higher sequence homology with these amino acid sequences.
[0186] 3. A composition comprising at least one cod trypsin ZT isoform according to embodiment 1 or 2, and suitable excipients and carriers.
[0187] 4. The composition according to embodiment 3, wherein the cod fish trypsin ZT isoform is present in the form of a mixture with other cod fish trypsins.
[0188] 5. The composition according to embodiment 4, wherein the codfish trypsin ZT isoform accounts for at least 5% (w / w) of the total content of codfish trypsin in the composition.
[0189] 6. A composition according to any one of embodiments 3 to 5, which is administered topically in the form of a lotion, hydrogel, oral spray or nasal spray.
[0190] 7. The composition according to any one of embodiments 3 to 6, further comprising a polyvalent alcohol, such as glycerol.
[0191] 8. A composition according to any one of embodiments 3 to 7 for use in therapy.
[0192] 9. The composition according to any one of embodiments 3 to 7, for use in the treatment or prevention of a disease caused by a pathogenic organism selected from the group consisting of viruses, bacteria, fungi, parasites and protozoa.
[0193] 10. A composition according to any one of embodiments 3 to 7 for use in the treatment or prevention of upper respiratory tract diseases caused by pathogenic organisms such as viruses, bacteria and fungi.
[0194] 11. A composition according to any one of embodiments 3 to 7 for use in the treatment or prevention of pain; acute inflammation; chronic inflammation; arthritis; joint inflammation; bursitis; osteoarthritis; rheumatoid arthritis; juvenile rheumatoid arthritis; septic arthritis; fibromyalgia; systemic lupus erythematosus; phlebitis; tendinitis; rash; psoriasis; acne; eczema; seborrheic eczema on the face; eczema on the hands, face or neck; foreskin infection; tinea pedis; fistula infection; local ulcer infection; umbilical infection in newborns; wrinkles; scars; keloids; furuncle; warts and allergic itching; hemorrhoids; fungal infections and immune disorders, including autoimmune diseases.
[0195] 12. A composition according to any one of embodiments 3 to 7 for use in the treatment of wound infections and burn wounds.
[0196] 13. A composition according to any one of embodiments 3 to 7 for use in removing necrotic or sloughed skin from otherwise healthy skin.
[0197] 14. A composition according to any one of embodiments 3 to 7 for cosmetic use.
[0198] 15. The composition for cosmetic use according to embodiment 14, further comprising other cosmetically active compounds.
[0199] 16. A method for treating a disease, comprising administering a therapeutically effective amount of the composition according to any one of embodiments 3 to 7 to a patient in need thereof.
[0200] 17. The method according to embodiment 16, wherein the disease is caused by a pathogenic organism selected from the group consisting of: viruses, bacteria, fungi, parasites and protozoa.
[0201] 18. The method according to embodiment 16, wherein the disease is an upper respiratory tract disease caused by pathogenic organisms such as viruses and bacteria.
[0202] 19. The method of embodiment 16, wherein the disease is selected from pain; acute inflammation; chronic inflammation; arthritis; joint inflammation; bursitis; osteoarthritis; rheumatoid arthritis; juvenile rheumatoid arthritis; septic arthritis; fibromyalgia; systemic lupus erythematosus; phlebitis; tendinitis; rash; psoriasis; acne; eczema; seborrheic eczema on the face; eczema on the hands, face or neck; foreskin infection; tinea pedis; fistula infection; local ulcer infection; umbilical infection in newborns; wrinkles; scars; keloids; furuncle; warts and allergic itching; hemorrhoids; fungal infections and immune disorders, including autoimmune diseases.
[0203] 20. The method of embodiment 16, wherein the disease is a wound infection or a burn wound.
[0204] 21. A method for preparing a cod trypsin ZT isoform comprising an amino acid sequence according to any one of SEQ ID NO: 2 to SEQ ID NO: 5, comprising
[0205] (i) preparing an aqueous extract of cod viscera,
[0206] (ii) subjecting the aqueous extract to at least one or chromatographic step, including an affinity chromatography step using a p-aminobenzamidine affinity ligand, and
[0207] (iii) desorption and elution of the cod fish trypsin ZT isoform bound to the p-aminobenzamidine affinity ligand.
[0208] 22. The method according to embodiment 21 further comprises at least one step using an anion exchange resin after the affinity chromatography step (ii).
[0209] 23. The method according to embodiment 21 further comprises at least one step using a cation exchange resin before the affinity chromatography step (ii).
[0210] 24. The method according to any one of embodiments 21 to 23, wherein the desorbed and eluted cod trypsin ZT isoform is sterile filtered using a filter having a pore size of 0.45 μm or less.
[0211] 25. A method according to any one of embodiments 21 to 24, wherein the cod trypsin ZT isoform is selected from trypsin ZT-1, comprising the amino acid sequence according to SEQ ID NO: 2; trypsin ZT-2, comprising the amino acid sequence according to SEQ ID NO: 3; trypsin ZT-3, comprising the amino acid sequence according to SEQ ID NO: 4; and trypsin ZT-4, comprising the amino acid sequence according to SEQ ID NO: 5, or a mixture thereof. Sequence Listing <110> Zymetech EHF <120> Novel trypsin isoforms and uses thereof <130> 21083149 <150> EP15178208.3 <151> 2015-07-24 <160> twenty three <170> PatentIn version 3.5 <210> 1 <211> 227 <212> PRT <213> Artificial sequence <220> <223> universal sequence <220> <221> MISC_FEATURE <222> (2) <223> Xaa can be I or V <220> <221> MISC_FEATURE <222> (5) <223> Xaa can be Q or H <220> <221> MISC_FEATURE <222> (6) <223> Xaa can be D or E <220> <221> MISC_FEATURE <222> (10)..(10) <223> Xaa can be R or N <220> <221> MISC_FEATURE <222> (77)..(77) <223> Xaa is L <220> <221> MISC_FEATURE <222> (148)..(148) <223> Xaa can be T or P <220> <221> MISC_FEATURE <222> (150)..(150) <223> Xaa can be D or A <220> <221> MISC_FEATURE <222> (152)..(152) <223> Xaa can be E or Q <220> <221> MISC_FEATURE <222> (154)..(154) <223> Xaa can be A or S <220> <221> MISC_FEATURE <222> (164)..(164) <223> Xaa can be V or M <220> <221> MISC_FEATURE <222> (166)..(166) <223> Xaa can be A or V <220> <221> MISC_FEATURE <222> (168)..(168) <223> Xaa can be Y or F <220> <221> MISC_FEATURE <222> (175)..(175) <223> Xaa can be A or V <220> <221> MISC_FEATURE <222> (198)..(198) <223> Xaa can be Q or R <220> <221> MISC_FEATURE <222> (202)..(202) <223> Xaa can be L or E <220> <221> MISC_FEATURE <222> (205)..(205) <223> Xaa can be Y or S <220> <221> MISC_FEATURE <222> (215)..(215) <223> Xaa can be Y or F <400> 1 Ile Xaa Gly Gly Xaa Xaa Cys Glu Pro Xaa Ser Arg Pro Phe Met Ala 1 5 10 15 Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly Gly Val Leu Ile Asn Asp 20 25 30 Gln Trp Val Leu Ser Val Ala His Cys Trp Tyr Asn Pro Tyr Tyr Met 35 40 45 Gln Val Met Leu Gly Glu His Asp Leu Arg Val Phe Glu Gly Thr Glu 50 55 60 Gln Leu Val Lys Thr Asn Thr Ile Phe Trp His Glu Xaa Tyr Asp Tyr 65 70 75 80 Gln Thr Leu Asp Tyr Asp Met Met Met Ile Lys Leu Tyr His Pro Val 85 90 95 Glu Val Thr Gln Ser Val Ala Pro Ile Ser Leu Pro Thr Gly Pro Pro 100 105 110 Asp Gly Gly Met Leu Cys Ser Val Ser Gly Trp Gly Asn Met Ala Met 115 120 125 Gly Glu Glu Val Asn Leu Pro Thr Arg Leu Gln Cys Leu Asp Val Pro 130 135 140 Ile Val Glu Xaa Val Xaa Cys Xaa Ala Xaa Tyr Pro Gly Met Ile Ser 145 150 155 160 Pro Arg Met Xaa Cys Xaa Gly Xaa Met Asp Gly Gly Arg Asp Xaa Cys 165 170 175 Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val Leu Thr Gly 180 185 190 Leu Val Ser Trp Gly Xaa Gly Cys Ala Xaa Pro Asn Xaa Pro Gly Val 195 200 205 Tyr Val Lys Val Tyr Glu Xaa Leu Ser Trp Ile Gln Thr Thr Leu Asp 210 215 220 Ala Asn Pro 225 <210> 2 <211> 227 <212> PRT <213> Atlantic cod <400> 2 Ile Val Gly Gly His Glu Cys Glu Pro Asn Ser Arg Pro Phe Met Ala 1 5 10 15 Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly Gly Val Leu Ile Asn Asp 20 25 30 Gln Trp Val Leu Ser Val Ala His Cys Trp Tyr Asn Pro Tyr Tyr Met 35 40 45 Gln Val Met Leu Gly Glu His Asp Leu Arg Val Phe Glu Gly Thr Glu 50 55 60 Gln Leu Val Lys Thr Asn Thr Ile Phe Trp His Glu Leu Tyr Asp Tyr 65 70 75 80 Gln Thr Leu Asp Tyr Asp Met Met Met Ile Lys Leu Tyr His Pro Val 85 90 95 Glu Val Thr Gln Ser Val Ala Pro Ile Ser Leu Pro Thr Gly Pro Pro 100 105 110 Asp Gly Gly Met Leu Cys Ser Val Ser Gly Trp Gly Asn Met Ala Met 115 120 125 Gly Glu Glu Val Asn Leu Pro Thr Arg Leu Gln Cys Leu Asp Val Pro 130 135 140 Ile Val Glu Pro Val Ala Cys Gln Ala Ser Tyr Pro Gly Met Ile Ser 145 150 155 160 Pro Arg Met Met Cys Val Gly Phe Met Asp Gly Gly Arg Asp Val Cys 165 170 175 Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val Leu Thr Gly 180 185 190 Leu Val Ser Trp Gly Arg Gly Cys Ala Glu Pro Asn Ser Pro Gly Val 195 200 205 Tyr Val Lys Val Tyr Glu Phe Leu Ser Trp Ile Gln Thr Thr Leu Asp 210 215 220 Ala Asn Pro 225 <210> 3 <211> 227 <212> PRT <213> Atlantic cod <400> 3 Ile Val Gly Gly His Glu Cys Glu Pro Asn Ser Arg Pro Phe Met Ala 1 5 10 15 Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly Gly Val Leu Ile Asn Asp 20 25 30 Gln Trp Val Leu Ser Val Ala His Cys Trp Tyr Asn Pro Tyr Tyr Met 35 40 45 Gln Val Met Leu Gly Glu His Asp Leu Arg Val Phe Glu Gly Thr Glu 50 55 60 Gln Leu Val Lys Thr Asn Thr Ile Phe Trp His Glu Leu Tyr Asp Tyr 65 70 75 80 Gln Thr Leu Asp Tyr Asp Met Met Met Ile Lys Leu Tyr His Pro Val 85 90 95 Glu Val Thr Gln Ser Val Ala Pro Ile Ser Leu Pro Thr Gly Pro Pro 100 105 110 Asp Gly Gly Met Leu Cys Ser Val Ser Gly Trp Gly Asn Met Ala Met 115 120 125 Gly Glu Glu Val Asn Leu Pro Thr Arg Leu Gln Cys Leu Asp Val Pro 130 135 140 Ile Val Glu Thr Val Asp Cys Glu Ala Ala Tyr Pro Gly Met Ile Ser 145 150 155 160 Pro Arg Met Val Cys Ala Gly Tyr Met Asp Gly Gly Arg Asp Ala Cys 165 170 175 Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val Leu Thr Gly 180 185 190 Leu Val Ser Trp Gly Gln Gly Cys Ala Leu Pro Asn Tyr Pro Gly Val 195 200 205 Tyr Val Lys Val Tyr Glu Tyr Leu Ser Trp Ile Gln Thr Thr Leu Asp 210 215 220 Ala Asn Pro 225 <210> 4 <211> 227 <212> PRT <213> Atlantic cod <400> 4 Ile Ile Gly Gly Gln Asp Cys Glu Pro Arg Ser Arg Pro Phe Met Ala 1 5 10 15 Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly Gly Val Leu Ile Asn Asp 20 25 30 Gln Trp Val Leu Ser Val Ala His Cys Trp Tyr Asn Pro Tyr Tyr Met 35 40 45 Gln Val Met Leu Gly Glu His Asp Leu Arg Val Phe Glu Gly Thr Glu 50 55 60 Gln Leu Val Lys Thr Asn Thr Ile Phe Trp His Glu Leu Tyr Asp Tyr 65 70 75 80 Gln Thr Leu Asp Tyr Asp Met Met Met Ile Lys Leu Tyr His Pro Val 85 90 95 Glu Val Thr Gln Ser Val Ala Pro Ile Ser Leu Pro Thr Gly Pro Pro 100 105 110 Asp Gly Gly Met Leu Cys Ser Val Ser Gly Trp Gly Asn Met Ala Met 115 120 125 Gly Glu Glu Val Asn Leu Pro Thr Arg Leu Gln Cys Leu Asp Val Pro 130 135 140 Ile Val Glu Pro Val Ala Cys Gln Ala Ser Tyr Pro Gly Met Ile Ser 145 150 155 160 Pro Arg Met Met Cys Val Gly Phe Met Asp Gly Gly Arg Asp Val Cys 165 170 175 Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val Leu Thr Gly 180 185 190 Leu Val Ser Trp Gly Arg Gly Cys Ala Glu Pro Asn Ser Pro Gly Val 195 200 205 Tyr Val Lys Val Tyr Glu Phe Leu Ser Trp Ile Gln Thr Thr Leu Asp 210 215 220 Ala Asn Pro 225 <210> 5 <211> 227 <212> PRT <213> Atlantic cod <400> 5 Ile Ile Gly Gly Gln Asp Cys Glu Pro Arg Ser Arg Pro Phe Met Ala 1 5 10 15 Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly Gly Val Leu Ile Asn Asp 20 25 30 Gln Trp Val Leu Ser Val Ala His Cys Trp Tyr Asn Pro Tyr Tyr Met 35 40 45 Gln Val Met Leu Gly Glu His Asp Leu Arg Val Phe Glu Gly Thr Glu 50 55 60 Gln Leu Val Lys Thr Asn Thr Ile Phe Trp His Glu Leu Tyr Asp Tyr 65 70 75 80 Gln Thr Leu Asp Tyr Asp Met Met Met Ile Lys Leu Tyr His Pro Val 85 90 95 Glu Val Thr Gln Ser Val Ala Pro Ile Ser Leu Pro Thr Gly Pro Pro 100 105 110 Asp Gly Gly Met Leu Cys Ser Val Ser Gly Trp Gly Asn Met Ala Met 115 120 125 Gly Glu Glu Val Asn Leu Pro Thr Arg Leu Gln Cys Leu Asp Val Pro 130 135 140 Ile Val Glu Thr Val Asp Cys Glu Ala Ala Tyr Pro Gly Met Ile Ser 145 150 155 160 Pro Arg Met Val Cys Ala Gly Tyr Met Asp Gly Gly Arg Asp Ala Cys 165 170 175 Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val Leu Thr Gly 180 185 190 Leu Val Ser Trp Gly Gln Gly Cys Ala Leu Pro Asn Tyr Pro Gly Val 195 200 205 Tyr Val Lys Val Tyr Glu Tyr Leu Ser Trp Ile Gln Thr Thr Leu Asp 210 215 220 Ala Asn Pro 225 <210> 6 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Fragment 1 <400> 6 Ile Ile Gly Gly Gln Asp Cys Glu Pro Arg 1 5 10 <210> 7 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Clip 2 <400> 7 Val Phe Glu Gly Thr Glu Gln Leu Val Lys 1 5 10 <210> 8 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Clip 3 <400> 8 Leu Gln Cys Leu Asp Val Pro Ile Val Glu Pro Val Ala Cys Gln Ala 1 5 10 15 Ser Tyr Pro Gly Met Ile Ser Pro Arg 20 25 <210> 9 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Clip 4 <400> 9 Leu Gln Cys Leu Asp Val Pro Ile Val Glu Thr Val Asp Cys Glu Ala 1 5 10 15 Ala Tyr Pro Gly Met Ile Ser Pro Arg 20 25 <210> 10 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Clip 5 <400> 10 Met Val Cys Ala Gly Tyr Met Asp Gly Gly Arg 1 5 10 <210> 11 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Clip 6 <400> 11 Met Met Cys Val Gly Phe Met Asp Gly Gly Arg 1 5 10 <210> 12 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Clip 7 <400> 12 Gly Cys Ala Glu Pro Asn Ser Pro Gly Val Tyr Val Lys 1 5 10 <210> 13 <211> 25 <212> PRT <213> Artificial sequence <220> <223> Clip 8 <400> 13 Asp Val Cys Asn Gly Asp Ser Gly Ser Pro Leu Val Cys Glu Gly Val 1 5 10 15 Leu Thr Gly Leu Val Ser Trp Gly Arg 20 25 <210> 14 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Clip 9 <400> 14 Gln Gly Lys Lys Ala Pro 1 5 <210> 15 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Clip 10 <400> 15 Trp Gly Asn Arg Ser Pro Leu Glu 1 5 <210> 16 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Clip 11 <400> 16 Gln Ala Val Arg Pro Asn Gly Met 1 5 <210> 17 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Clip 12 <400> 17 Phe Asp Asn Arg Val Gly Lys Trp 1 5 <210> 18 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Clip 13 <400> 18 Ile Ala Arg Gln Pro Trp Asn 1 5 <210> 19 <211> 250 <212> PRT <213> Atlantic cod <400> 19 Met Ile Gly Leu Ala Leu Leu Met Leu Leu Gly Ala Ala Ala Ala Ala 1 5 10 15 Val Pro Arg Asp Val Gly Lys Ile Val Gly Gly His Glu Cys Glu Pro 20 25 30 Asn Ser Arg Pro Phe Met Ala Ser Leu Asn Tyr Gly Tyr His Phe Cys 35 40 45 Gly Gly Val Leu Ile Asn Asp Gln Trp Val Leu Ser Val Ala His Cys 50 55 60 Trp Tyr Asn Pro Tyr Tyr Met Gln Val Met Leu Gly Glu His Asp Leu 65 70 75 80 Arg Val Phe Glu Gly Thr Glu Gln Leu Val Lys Thr Asn Thr Ile Phe 85 90 95 Trp His Glu Leu Tyr Asp Tyr Gln Thr Leu Asp Tyr Asp Met Met Met 100 105 110 Ile Lys Leu Tyr His Pro Val Glu Val Thr Gln Ser Val Ala Pro Ile 115 120 125 Ser Leu Pro Thr Gly Pro Pro Asp Gly Gly Met Leu Cys Ser Val Ser 130 135 140 Gly Trp Gly Asn Met Ala Met Gly Glu Glu Val Asn Leu Pro Thr Arg 145 150 155 160 Leu Gln Cys Leu Asp Val Pro Ile Val Glu Pro Val Ala Cys Gln Ala 165 170 175 Ser Tyr Pro Gly Met Ile Ser Pro Arg Met Met Cys Val Gly Phe Met 180 185 190 Asp Gly Gly Arg Asp Val Cys Asn Gly Asp Ser Gly Ser Pro Leu Val 195 200 205 Cys Glu Gly Val Leu Thr Gly Leu Val Ser Trp Gly Arg Gly Cys Ala 210 215 220 Glu Pro Asn Ser Pro Gly Val Tyr Val Lys Val Tyr Glu Phe Leu Ser 225 230 235 240 Trp Ile Gln Thr Thr Leu Asp Ala Asn Pro 245 250 <210> 20 <211> 250 <212> PRT <213> Atlantic cod <400> 20 Met Ile Gly Leu Ala Leu Leu Met Leu Leu Gly Ala Ala Ala Ala Ala 1 5 10 15 Val Pro Arg Asp Val Gly Lys Ile Val Gly Gly His Glu Cys Glu Pro 20 25 30 Asn Ser Arg Pro Phe Met Ala Ser Leu Asn Tyr Gly Tyr His Phe Cys 35 40 45 Gly Gly Val Leu Ile Asn Asp Gln Trp Val Leu Ser Val Ala His Cys 50 55 60 Trp Tyr Asn Pro Tyr Tyr Met Gln Val Met Leu Gly Glu His Asp Leu 65 70 75 80 Arg Val Phe Glu Gly Thr Glu Gln Leu Val Lys Thr Asn Thr Ile Phe 85 90 95 Trp His Glu Leu Tyr Asp Tyr Gln Thr Leu Asp Tyr Asp Met Met Met 100 105 110 Ile Lys Leu Tyr His Pro Val Glu Val Thr Gln Ser Val Ala Pro Ile 115 120 125 Ser Leu Pro Thr Gly Pro Pro Asp Gly Gly Met Leu Cys Ser Val Ser 130 135 140 Gly Trp Gly Asn Met Ala Met Gly Glu Glu Val Asn Leu Pro Thr Arg 145 150 155 160 Leu Gln Cys Leu Asp Val Pro Ile Val Glu Thr Val Asp Cys Glu Ala 165 170 175 Ala Tyr Pro Gly Met Ile Ser Pro Arg Met Val Cys Ala Gly Tyr Met 180 185 190 Asp Gly Gly Arg Asp Ala Cys Asn Gly Asp Ser Gly Ser Pro Leu Val 195 200 205 Cys Glu Gly Val Leu Thr Gly Leu Val Ser Trp Gly Gln Gly Cys Ala 210 215 220 Leu Pro Asn Tyr Pro Gly Val Tyr Val Lys Val Tyr Glu Tyr Leu Ser 225 230 235 240 Trp Ile Gln Thr Thr Leu Asp Ala Asn Pro 245 250 <210> 21 <211> 249 <212> PRT <213> Atlantic cod <400> 21 Met Ile Gly Leu Ala Leu Leu Met Leu Leu Gly Ala Ala Ala Ala Val 1 5 10 15 Pro Arg Glu Asp Gly Arg Ile Ile Gly Gly Gln Asp Cys Glu Pro Arg 20 25 30 Ser Arg Pro Phe Met Ala Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly 35 40 45 Gly Val Leu Ile Asn Asp Gln Trp Val Leu Ser Val Ala His Cys Trp 50 55 60 Tyr Asn Pro Tyr Tyr Met Gln Val Met Leu Gly Glu His Asp Leu Arg 65 70 75 80 Val Phe Glu Gly Thr Glu Gln Leu Val Lys Thr Asn Thr Ile Phe Trp 85 90 95 His Glu Leu Tyr Asp Tyr Gln Thr Leu Asp Tyr Asp Met Met Met Ile 100 105 110 Lys Leu Tyr His Pro Val Glu Val Thr Gln Ser Val Ala Pro Ile Ser 115 120 125 Leu Pro Thr Gly Pro Pro Asp Gly Gly Met Leu Cys Ser Val Ser Gly 130 135 140 Trp Gly Asn Met Ala Met Gly Glu Glu Val Asn Leu Pro Thr Arg Leu 145 150 155 160 Gln Cys Leu Asp Val Pro Ile Val Glu Pro Val Ala Cys Gln Ala Ser 165 170 175 Tyr Pro Gly Met Ile Ser Pro Arg Met Met Cys Val Gly Phe Met Asp 180 185 190 Gly Gly Arg Asp Val Cys Asn Gly Asp Ser Gly Ser Pro Leu Val Cys 195 200 205 Glu Gly Val Leu Thr Gly Leu Val Ser Trp Gly Arg Gly Cys Ala Glu 210 215 220 Pro Asn Ser Pro Gly Val Tyr Val Lys Val Tyr Glu Phe Leu Ser Trp 225 230 235 240 Ile Gln Thr Thr Leu Asp Ala Asn Pro 245 <210> 22 <211> 249 <212> PRT <213> Atlantic cod <400> 22 Met Ile Gly Leu Ala Leu Leu Met Leu Leu Gly Ala Ala Ala Ala Val 1 5 10 15 Pro Arg Glu Asp Gly Arg Ile Ile Gly Gly Gln Asp Cys Glu Pro Arg 20 25 30 Ser Arg Pro Phe Met Ala Ser Leu Asn Tyr Gly Tyr His Phe Cys Gly 35 40 45 Gly Val Leu Ile Asn Asp Gln Trp Val Leu Ser Val Ala His Cys Trp 50 55 60 Tyr Asn Pro Tyr Tyr Met Gln Val Met Leu Gly Glu His Asp Leu Arg 65 70 75 80 Val Phe Glu Gly Thr Glu Gln Leu Val Lys Thr Asn Thr Ile Phe Trp 85 90 95 His Glu Leu Tyr Asp Tyr Gln Thr Leu Asp Tyr Asp Met Met Met Ile 100 105 110 Lys Leu Tyr His Pro Val Glu Val Thr Gln Ser Val Ala Pro Ile Ser 115 120 125 Leu Pro Thr Gly Pro Pro Asp Gly Gly Met Leu Cys Ser Val Ser Gly 130 135 140 Trp Gly Asn Met Ala Met Gly Glu Glu Val Asn Leu Pro Thr Arg Leu 145 150 155 160 Gln Cys Leu Asp Val Pro Ile Val Glu Thr Val Asp Cys Glu Ala Ala 165 170 175 Tyr Pro Gly Met Ile Ser Pro Arg Met Val Cys Ala Gly Tyr Met Asp 180 185 190 Gly Gly Arg Asp Ala Cys Asn Gly Asp Ser Gly Ser Pro Leu Val Cys 195 200 205 Glu Gly Val Leu Thr Gly Leu Val Ser Trp Gly Gln Gly Cys Ala Leu 210 215 220 Pro Asn Tyr Pro Gly Val Tyr Val Lys Val Tyr Glu Tyr Leu Ser Trp 225 230 235 240 Ile Gln Thr Thr Leu Asp Ala Asn Pro 245 <210> 23 <211> 12 <212> PRT <213> Atlantic cod <400> 23 Cys Val Leu Ser Gly Trp Val Arg Asp Thr Met Ala 1 5 10
Claims
1. An isolated cod trypsin ZT isoform having an amino acid sequence having 99% or greater sequence identity with the amino acid sequence according to SEQ ID NO: 2, wherein the trypsin ZT isoform is derived from Atlantic cod (Gadus morhua).
2. A composition comprising at least one cod trypsin ZT isoform according to claim 1, and suitable excipients and carriers.
3. The composition according to claim 2, wherein the cod fish trypsin ZT isoform is present in the form of a mixture with other cod fish trypsins.
4. The composition of claim 3, wherein the cod fish trypsin ZT isoform comprises at least 5% (w / w) of the total content of cod fish trypsin in the composition.
5. A composition according to any one of claims 2 to 4 for topical administration in the form of a lotion, hydrogel, oral spray or nasal spray.
6. The composition of any one of claims 2 to 4, further comprising a polyvalent alcohol.
7. The composition of claim 6, wherein the polyvalent alcohol is glycerol.
8. The composition according to any one of claims 2 to 4, for use in the treatment or prevention of upper respiratory tract diseases caused by viruses.
9. A composition according to any one of claims 2 to 4 for cosmetic use.
10. The composition for cosmetic use according to claim 9, further comprising other cosmetically active compounds.
11. Use of a therapeutically effective amount of the composition according to any one of claims 2 to 7 for the preparation of a medicament for treating a disease, wherein the disease is an upper respiratory tract disease caused by a virus.
